Alla studier
RekryteringPHASE2, PHASE3INTERVENTIONELL

AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

This research is looking into a new gene therapy, RGX-202, for Duchenne muscular dystrophy (DMD). DMD is a condition where muscles weaken over time because a vital protein called dystrophin is missing. RGX-202 is designed to help muscle cells make a working version of this protein. The study will test how safe the treatment is, how well people tolerate it, and if it helps improve muscle strength. It's a multi-stage study, starting with a smaller group to check safety, then expanding to more boys. Participants will receive a single treatment given through a drip, and their health will be monitored for about two years afterwards.

Överblick

Status
Rekrytering
Fas
PHASE2, PHASE3
Sponsor
REGENXBIO Inc.
Inskrivningsmål
65
Starta
04 Jan 2023
Beräknad slutförande
01 aug 2028

Vad handlar denna studie om?

Duchenne muscular dystrophy (DMD) is a genetic condition that causes muscles to become weak and waste away over time. This happens because the body can't make enough of a key protein called dystrophin, which is essential for healthy muscle function. Without it, muscle cells get damaged, leading to ongoing problems.

This study is investigating a new treatment called RGX-202. It's a type of gene therapy, which means it works by introducing new genetic information into the body. Specifically, RGX-202 aims to deliver a piece of genetic code to muscle cells. This code acts like a 'recipe' for a special, smaller version of the dystrophin protein that can still help muscles work.

The main goals of this research are to find out if RGX-202 is safe, if boys with DMD can tolerate the treatment well, and if it helps improve their muscle strength and function. The treatment is given once, through a drip into the vein. Boys in the study will also receive other medicines for a short time to prevent their body from reacting negatively to the gene therapy.

Viktiga punkter

  • Tests a new gene therapy (RGX-202) for Duchenne muscular dystrophy.
  • Aims to help muscles make a working version of a missing protein.
  • Treatment is a single dose given into a vein.
  • Study monitors participants for around two years after treatment.
  • Participants will also take short-term medicines to help with the treatment.
  • Open to male participants aged 1 to <12 years old.

Vem kan vara berättigad?

This study is looking for boys who have Duchenne muscular dystrophy. They need to be male and at least 1 year old, but less than 12 years old. They should also meet a certain weight requirement (at least 10 kg).

To be considered, participants generally need to have specific changes in their DMD gene and may need to be able to walk a certain distance independently. They should also have been on a stable dose of steroid medication (a common treatment for DMD) for at least 12 weeks. Your doctor will check your child's general health, including their liver and kidney function, to make sure they are healthy enough to take part.

It's important that the child's parent or legal guardian understands the study and agrees to participate, and that they can bring their child to all scheduled appointments and follow the study instructions.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Is my child male and between 1 and 12 years old?
  2. Does my child have a confirmed diagnosis of Duchenne muscular dystrophy?
  3. Can my child walk independently, or with minimal help (depending on the specific group)?
  4. Has my child been on a steady dose of steroid medication for at least 3 months?
  5. Are we able and willing to attend all study appointments over about two years?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you join this study, your child will receive the RGX-202 treatment once, through a drip into their vein. Before and during the treatment, your child will also take other medicines for a short time to help prevent any strong reactions to the gene therapy.

The study involves regular visits to the clinic over roughly two years to check your child's health, how they are tolerating the treatment, and if their muscles are improving. These visits will include various assessments, such as physical examinations, blood tests, and tests to measure muscle strength and function. After the main study period, there might be an option to join a separate long-term follow-up study to continue monitoring your child's health.

Potentiella risker och fördelar

Taking part in any clinical trial involves both potential benefits and risks. The potential benefit of this study is that RGX-202 could help improve muscle strength and overall health for boys with Duchenne muscular dystrophy. However, as this is a new treatment, there might be side effects or risks that are not yet fully known. The study team will carefully monitor your child for any problems, and you'll be given detailed information about known risks. Remember, participation is completely voluntary, and you have the right to withdraw your child from the study at any time, for any reason, without it affecting their future medical care.

Platser (17)

  • Arkansas Children's Hospital
    Verifierat postnummer
    Little Rock, USA· Rekrytering
  • Stanford School of Medicine /Division of Neuromuscular Medicine
    Verifierat postnummer
    Palo Alto, USA· Rekrytering
  • Barnsjukhuset Colorado
    Verifierat postnummer
    Aurora, USA· Rekrytering
  • Universitetet i Florida
    Verifierat postnummer
    Gainesville, USA· Rekrytering
  • Rare Disease Research
    Verifierat postnummer
    Atlanta, USA· Rekrytering
  • Ann & Robert H. Lurie Barnsjukhus i Chicago
    Verifierat postnummer
    Chicago, USA· Rekrytering
  • University of Iowa
    Verifierat postnummer
    Iowa City, USA· Rekrytering
  • University of Massachusetts Chan Medical School
    Verifierat postnummer
    Worcester, USA· Rekrytering
  • Cincinnati Children's
    Verifierat postnummer
    Cincinnati, USA· Rekrytering
  • Oregon Health & Science University
    Verifierat postnummer
    Portland, USA· Rekrytering
  • The University of Texas Southwestern Medical Center
    Verifierat postnummer
    Dallas, USA· Rekrytering
  • Kungens Döttrars Barnsjukhus
    Verifierat postnummer
    Norfolk, USA· Rekrytering

Vanliga frågor

Vad är Duchennes muskeldystrofi?

It's a genetic condition that causes muscles to become weak and waste away over time because the body can't make enough of a protein called dystrophin.

What is RGX-202?

It's a new gene therapy treatment designed to help muscle cells make a useful, smaller version of the missing dystrophin protein.

Hur ges behandlingen?

It's given once as a single injection into a vein (like a drip).

Hur länge kommer mitt barn att vara med i studien?

Participants will be monitored for about two years after receiving the treatment, with regular check-ups.

Can girls join the study?

No, this specific study is only for male participants.

Hur du får reda på mer

Patient Advocacy

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With…" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.